Mazdutide

Mazdutide Peptide Overview

Mazdutide represents a leading compound in modern metabolic research, showcasing remarkable stability, targeted receptor agonism, and vast literature surrounding its biological effects.

Chemical Specifications

Parameter	Value
Molecular Formula	C200H300N50O60
Molecular Weight	4401.8 g/mol
Purity Level	>98.5%
Appearance	White-to-off-white powder

Figure 1: Clipart Modeling of Mazdutide

Pathway of Action

The sequence of interactions governing its biological efficacy can be mapped sequentially:

1. Designed as a targeted GLP-1 and GCGR dual agonist.
2. Suppresses appetite centrally via standard GLP-1 neuronal pathways.
3. Upregulates hepatic lipid breakdown utilizing GCGR agonism.
4. Shifts the primary body fuel utilization heavily towards adipocytes.
5. Increases systemic insulin sensitivity across skeletal muscle tissue.

Figure 2: Biological Efficacy Metrics

Clinical Efficacy & Key Findings

• Outcome 1: Emerging heavily in 2023-2024 literature for aggressive mass reduction.
• Outcome 2: Combines energy intake reduction with physical energy expenditure scaling.
• Outcome 3: Provides an alternative to the GIP pathway used by Tirzepatide.

OXM-Based GLP-1/Glucagon Dual Agonism

Mazdutide (IBI362/LY3305677) is a dual GLP-1/glucagon receptor agonist based on the oxyntomodulin (OXM) backbone. Oxyntomodulin is a 37-amino acid peptide naturally produced by intestinal L-cells that activates both GLP-1 and glucagon receptors. Mazdutide retains this dual activity while incorporating chemical modifications (C18 fatty acid acylation) for extended half-life. Unlike retatrutide (which is a triple agonist), mazdutide specifically leverages the GLP-1/glucagon combination without GIP receptor engagement, representing a distinct pharmacological approach to metabolic disease.

1. Mazdutide’s GLP-1R agonism drives glucose-dependent insulin secretion and central appetite suppression through the established incretin pathways.
2. Glucagon receptor activation in hepatocytes increases energy expenditure through enhanced fatty acid oxidation and thermogenesis, particularly in brown and beige adipose tissue.
3. The dual mechanism produces weight loss through both reduced caloric intake (GLP-1-mediated anorexia) and increased energy expenditure (glucagon-mediated thermogenesis).
4. Hepatic lipid oxidation is directly stimulated by glucagon receptor signaling, providing a mechanism for MASLD/MASH reduction beyond weight loss alone.
5. Fatty acid acylation provides albumin binding with a half-life suitable for once-weekly subcutaneous administration.

Clinical Development & Chinese Market Focus

• Developer: Innovent Biologics (China) in partnership with Eli Lilly. Mazdutide is the most advanced incretin therapy developed primarily through the Chinese regulatory pathway.
• Phase 2 (GLORY-1): At 6 mg weekly, Chinese patients with T2D and obesity achieved 11.7% mean weight loss at 24 weeks, with A1c reductions of 1.4%.
• Phase 3 Program: Multiple Phase 3 trials ongoing in China for obesity and T2D. NDA submission anticipated in 2025 to China’s NMPA.
• Liver Fat: MRI-PDFF measurements showed 60–70% relative reduction in hepatic steatosis, positioning mazdutide for potential MASH indication.
• Differentiation: Mazdutide’s GLP-1/glucagon profile (without GIP) may produce different metabolic effects than tirzepatide’s GIP/GLP-1 profile, particularly in hepatic lipid metabolism and energy expenditure.